A dedicated specimen (i.e. no other tests to be performed) is required for this assay.
DO NOT USE HEPARIN TUBES
Do not use serum samples
Do not use PPT tubes
Do not separate EDTA samples
4 mL EDTA Whole Blood (Always Required) 600 uL Micro-EDTA Whole Blood Assay Method
Primers and probe in this assay amplify a 133-bp fragment of the highly conserved U67 open reading frame of HHV-6
Collect into a sterile CSF tube, do not dilute.
0.5 mL Sterile Container CSF (Always Required) Turnaround Time:
Tests performed as requested. Result available within 3 days.
Specimen Collection Sterile Container Tissue (Always Required) Turnaround Time: Between 1 day and 3 days Diagnostic Use and Interpretation
HHV6, first isolated in 1986 from lymphocytes, is a widespread betaherpesvirus genetically related to human cytomegalovirus (HCMV).
Two major species HHV-6A and HHV-6B are recognised. They differ at biological, immunological and molecular levels as well as prevalence and disease association. Most viral isolates responsible for symptomatic primary infection belong to the B sub-group. A sub-group isolates have been less commonly detected in immunosuppressed adults.
HHV6 induces a lifelong latent infection in humans. Unlike other human herpesviruses, genomic HHV-6 is covalently integrated into the subtelomeric region of cell chromosomes (ciHHV-6) in about 1% of the population. Although infrequent, this may be a confounding factor for the diagnosis of active viral infection.
The primary clinical manifestations in early childhood include exanthem subitum ( Roseola /rash) characterised by high fever, sometimes with seizures, generalised rash and granulocytopenia.
Meningoencephalitis, fulminant hepatitis and other organ involvement are rarer complications of primary infection.
Approximately 75% of people are infected by one year of age with HHV6 which thereafter persists for life.
Infection or reinfection is generally associated with some immunological abnormality and in immunosuppressed hosts fever, rash, encephalitis, pneumonitis, transplant rejection-especially renal and bone marrow- are associated with HHV6 infection.
Laboratory diagnosis in immunosuppressed patients by seroconversion or qualitative PCR are not ideal clinically due to high rate of seropositivity (approaching 100% at age 2 years) and frequency of positive PCR in sites such as blood, saliva and brain.
Quantitative and real-time PCR may be more useful for delineating disease associations by following viral load in blood. Note that in chromosomally integrated HHV-6, each cell contains a copy of HHV-6. High levels of HHV-6 (>million copies per ml whole blood) therefore pose a diagnostic problem and are highly suggestive of ciHHV-6.
The antiviral compounds ganciclovir, foscarnet and cidofovir are effective against active HHV-6 infections but indications tor treatment are not formally approved to date.
For further information contact the laboratory (contact via Lablink: 22000 or (09) 307-8995 or 0800 522 7587) ,or:
the Virology team email@example.com